Clinical Efficacy and Safety of Decitabine in Treatment of 37 Cases of Myelodysplastic Syndrome

Qin Jian; Huang Shan; Nie Bo

Volume 38 Issue 10

Turn off MathJax

Article Contents

Abstract

References

Relative Articles

Article Navigation > Journal of Kunming Medical University > 2017 > 38(10): 112-116

Zhu Yu Ling , Liu Ping , Tian Zheng , Zhang Fu Rong , Yang Mai Qiao . Anesthetic effect of Different Doses of Bupivacaine in Cesarean Section under Combined Spinal-epidural Anesthesia[J]. Journal of Kunming Medical University, 2019, 40(03): 73-77.

Citation:

Qin Jian , Huang Shan , Nie Bo . Clinical Efficacy and Safety of Decitabine in Treatment of 37 Cases of Myelodysplastic Syndrome[J]. Journal of Kunming Medical University, 2017, 38(10): 112-116.

Citation:

Qin Jian , Huang Shan , Nie Bo . Clinical Efficacy and Safety of Decitabine in Treatment of 37 Cases of Myelodysplastic Syndrome[J]. Journal of Kunming Medical University, 2017, 38(10): 112-116.

PDF( 219 KB)

Clinical Efficacy and Safety of Decitabine in Treatment of 37 Cases of Myelodysplastic Syndrome

Funds:

基金：云南省科技厅-昆明医科大学应用基础研究联合专项基金资助项目 (2014FB027);

Received Date: 2017-04-22

Abstract

Abstract

Objective To discuss the clinical efficacy and safety of an standard dosage of decitabine in the treatment of patients with myelodysplastic syndromes. Methods Totally 37 cases of MDS patients received the treatment of standard dose of decitabine, (20 mg/m2 each day, 5 days continued, each four weeks is a course of treatment) , which admitted in Hematology department of the First Affiliated Hospital of Kunming Medical University from January 2014 to December 2016. According to the established therapeutic regimen, collecting treatment effects and safety parameters of patients, and according to different groups factors to analyze the difference of effects. Results Twenty patients (54.1%) obtained the clinical effect after the treatment of decitabineafter at least 4 courses. There were 3 cases (8.10%) with complete remission (CR) , marrow CR (m CR) without hematological improvement (HI) in 6 cases (16.2%) , m CR with HI in 3 cases (8.1%) , and HI alone in 8 cases (21.6%) ; 3 cases (8.1%) achieved transfusion independence, and 11 cases (29.7%) with stable disease (SD) and 3 cases (8.1%) with progressive disease (PD) . The total response rate of MDS was calculated according to the patient age, WHO type and prognosis risk stratification, decitabine treatment of 65 patients under the age of ORR above, more than 65 patients of/RAEB RAEB-1-2 type ORR is higher than other types of patient, but the difference was not statistically significant (The 2 values were 0.815 and 1.213, P>0.05) . The ORR of patients with high risk group of IPSS prognostic risk score was significantly better than that of low-risk group, the difference was statistically significant (χ2=4.063, P=0.044) .The ORR of the high-risk group of WPSS prognosis was significantly better than that of the lower risk group, the difference was statistically significant (χ2=4.375, P=0.036) .Adverse reactions were most commonly seen in Blood platelet count decreased, white blood cell count decreased and medium granulocyte count decreased. Thehighest incidence of platelet count decreased, white blood cell count decreased and medium granulocyte count decreased that was found in 3 ~ 4 adverse reactions. The incidence rate was 65.5%, 59.3% and 53.8% respectively. Non-hematological adverse reactions mainly include infection, ALT, diarrhea and rashes, and most grades are given priority to 1 ~ 2 level. Conclusion Decitabine for treatment of MDS is well tolerated, and the adverse reactions occur reasonably and controllable, it can achieve the expected curative effect.
- Myelodysplastic syndrome,
- Decitabine,
- Adverse reactions

FullText(HTML)

References(12)

References

[1]	[1] KANTARJIAN H, OKI Y, GARCIA-MANERO G, et al.Results of a randomized study of 3 schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia[J].Blood, 2007, 109 (1) :52-57.
[2]	[2]LEE J H, JANG J H, PARK J, et al.A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome[J].Haematologica, 2011, 96 (10) :1441-1447.
[3]	[3]STEENSMA D P, BAER M R, SLACK J L, et al.Multicenter study of decitabine administered daily for 5 days every 4weeks to adults with myelodysplastic syndromes:the alternative dosing for outpatient treatment (ADOPT) trial[J].J Clin Oncol, 2009, 27 (27) :3842-3848.
[4]谢伟成, 程淑琴, 林翠芳.等.地西他滨治疗骨髓增生异常综合征的临床疗效研究[J].临床和实验医学杂志, 2014, 13 (11) :877-800.
[5]毛建平, 朱华渊, 沈文怡, 等.超小剂量地西他滨治疗骨髓增生异常综合征37例疗效及安全性评价[J].中国实用内科杂志, 2017, 37 (2) :141-144.
[6]	[6]SAUNTHARARAJAH Y.Key clinical observations after5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes[J].Hematol Am Soc Hematol Educ Program, 2013, 2013 (1) :511-521.
[7] 邵宗鸿.中高危骨髓增生异常综合征的治疗选择[J].中华血液学杂志, 2012, 33 (7) :508-511.
[8]	[8]LBBERT M, SUCIU S, BAILA L, et al.Low-dose decitabine versus best supportive care in elderly patients with Inter-mediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy:final results of therandomized phaseⅢstudy of the European Organisationfor Research and Treatment of Cancer Leukemia Groupand the German MDS Study Group[J].J Clin Oncol, 2011, 29 (15) :1987-1996.
[9]	[9]WANG J, YI Z, WANG S, et al.The effect of decitabine on megakaryocyte maturation and platelet release[J].Thromb Haemost, 2011, 106 (2) :337-343.
[10]李杰平, 曾东风, 朱丽丹, 等.地西他滨治疗中、高危骨髓增生异常综合征的临床观察[J].中国药房, 2013, 24 (40) :3764-3767.
[11]许倩, 孙爱宁, 陈苏宁, 等.多疗程地西他滨治疗骨髓增生异常综合征及急性髓系白血病患者的回顾性分析[J].临床血液学杂志, 2017, 30 (3) :198-201, 205.
[12]田雅兰, 边桂芝, 张志勇.地西他滨上市后血液及淋巴系统疾病不良反应信号检测与分析[J].中国医院药学杂志, 2017, 37 (14) :1401-1404.

Relative Articles(20)

Relative Articles

[1]	Wenxiu XU, Xiaofeng MO, Xiangmin YANG, Silu YANG, Fan WU, Te LI. Application of Logistic Regression and Decision Tree Model in Prediction of Adverse Reactions of Iodinated Contrast Medium. Journal of Kunming Medical University, 2024, 45(9): 70-75. doi: 10.12259/j.issn.2095-610X.S20240911
[2]	Zhen XU, Yu LING, Sixiang LIU, Yu SONG, Yang PENG, Jingjing SUN. Adverse Reactions of Vaccine Vaccination in Children with Special Health Conditions in Kunming and Countermeasures. Journal of Kunming Medical University, 2024, 45(3): 141-145. doi: 10.12259/j.issn.2095-610X.S20240321
[3]	Rong ZHANG, Xingju SONG, Lin Duan, Qian LI, Xu CHEN. Effect of Butylphthalide on NIHSS and Hemorheology in Patients with Acute Cerebral Infarction. Journal of Kunming Medical University, 2022, 43(8): 66-71. doi: 10.12259/j.issn.2095-610X.S20220810
[4]	Hao YANG, Guo-yun ZHANG, De-cai WANG, Yun-rui GUO, Ye-cai ZHANG, Jian-ming YANG. The Effect of Femoral Nerve Block and Oral Analgesia Guided by B-ultrasound on Preoperative Analgesia of Middle and Upper Femoral Fractures in Elderly Patients. Journal of Kunming Medical University, 2021, 42(9): 138-143. doi: 10.12259/j.issn.2095-610X.S20210931
[5]	Na LI, Jie CHEN, Ji LUO, Yong-gang CHEN, Jiang-li PENG, Ming-li YU, Sheng-hao LI. Retrospective Analysis of 376 Cases of Adverse Reactions to Antituberculosis Drug. Journal of Kunming Medical University, 2021, 42(4): 117-121. doi: 10.12259/j.issn.2095-610X.S20210422
[6]	Ye Ji Ming , Gu Xue Zhong , Chu Yu Yan , Liu Yu , Ye Ji Yun . . Journal of Kunming Medical University, 2020, 41(03): 72-76.
[7]	Cao Hong Hua , Wu Na , He Ming , Zhang Rui , Zhou Ye Ying , Lai Xuan , Shen Zheng Lei . . Journal of Kunming Medical University, 2019, 40(05): 49-52.
[8]	Li De Ying , Wang Yu Ming , Chai Hua Xiang , Dong Wei Qun . . Journal of Kunming Medical University, 2019, 40(11): 59-62.
[9]	Sun Jian Ming , Dong Fang . Adverse Reactions in Children with Acute Lymphoblastic Leukemia after Chemotherapy. Journal of Kunming Medical University, 2017, 38(10): 107-111.
[10]	Xiong Shou Qing . Comparison of Curative Effects and Complications of Coronary Intervention through Radial Artery and Femoral Artery. Journal of Kunming Medical University,
[11]	Liu Qing Hua . The Effect of Propofor Combined with Shufen on Analgesia，Analepsia and Adverse Reactions of Laparoscopic Myomectomy. Journal of Kunming Medical University,
[12]	Liu Ping . Effect of Intravenous Injection of Dezocine on the Incidence of Adverse Reactions during the Operation of Cesarean Delivery. Journal of Kunming Medical University,
[13]	Gui Qi . . Journal of Kunming Medical University,
[14]	Xing Wen Zhong . . Journal of Kunming Medical University,
[15]	Xu Ying Fang . . Journal of Kunming Medical University,
[16]	Tang Hui Rong . . Journal of Kunming Medical University,
[17]	Zhang Ying . . Journal of Kunming Medical University,
[18]	. The Clinical Observation of Modified Chinese Angelica Cold Limbs Decoction on Hand-foot Synsdrome Caused by Capecitabine. Journal of Kunming Medical University,
[19]	. The Clinical Analysis of 60 Cases of Adverse Reactions caused by Blood Transfusion. Journal of Kunming Medical University,
[20]	Tan Jing . . Journal of Kunming Medical University,

Supplements(0)

Cited By

Cited by

Periodical cited type(8)

1.	丁娅. 疏风宣肺止咳汤联合穴位敷贴治疗咳嗽变异性哮喘风邪犯肺证的临床观察. 中国民间疗法. 2022(01): 91-93 .
2.	曹琳，吴晓玲. 乙酰半胱氨酸雾化吸入联合常规抗结核方案治疗重症肺结核的效果及对炎性因子、MALAT1、IP-10、MMP-9水平的影响. 临床医学研究与实践. 2022(05): 34-37 .
3.	岳敬卫，王燕，张敏. 维生素D联合孟鲁司特对咳嗽变异性哮喘患儿的临床疗效及对IL-17与Treg的影响分析. 河北医学. 2022(05): 873-877 .
4.	焦春燕，焦咏梅，赵曌. 哮喘-慢阻肺重叠综合征患者免疫球蛋白、辅助性T细胞17和调节性T细胞与肺功能的相关性. 河南医学研究. 2022(05): 858-862 .
5.	钱星佳，吕红，陆兵，余静，陶政正. 风痰方介导TLR2TH17IL-17应答轴治疗咳嗽变异性哮喘的新机制研究. 中外医学研究. 2021(13): 29-31 .
6.	焦蕊，庞立健，吕晓东. 基于网络药理学探讨三拗汤治疗咳嗽变异型哮喘的作用机制. 中华全科医学. 2021(07): 1218-1223 .
7.	郑芳，卞相丽，李妙晨，吴志敏. 沙美特罗替卡松气雾剂联合粉尘螨滴剂舌下免疫治疗尘螨过敏性哮喘的临床效果. 河北医科大学学报. 2021(10): 1180-1184 .
8.	刘新学. 药物治疗咳嗽变异性哮喘患儿的效果观察. 深圳中西医结合杂志. 2020(10): 110-111 .